Get the Stockscreener App
3.015
2.33%
0.005
Recursion Pharmaceuticals Inc stock is traded at $3.015, with a volume of 4.51M.
It is up +2.33% in the last 24 hours and down -12.25% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.01
Open:
$3.03
24h Volume:
4.51M
Relative Volume:
0.33
Market Cap:
$1.60B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.5079
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
+8.07%
1M Performance:
-12.25%
6M Performance:
-30.16%
1Y Performance:
-24.51%
1-Day Range:
$3.00
$3.14
1-Week Range:
$2.81
$3.17
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.01 | 1.60B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Globe and Mail
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? - The Motley Fool
Recursion Pharmaceuticals (RXRX) Hits 52-Week Low; Is It In Oversold Territory? - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Mixed Signals Emerge On Future Growth Prospects - Yahoo Finance
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Morgan Stanley Raises its Price Target on Recursion (RXRX) - Insider Monkey
8 Most Oversold AI Stocks to Buy According to Analysts - Insider Monkey
RXRX (NASDAQ) Form 144: 40,000 Class A shares proposed sale via Fidelity - Stock Titan
Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet? - Sahm
Recursion Pharmaceuticals (RXRX) price target decreased by 10.64% to 6.12 - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI Drug Discovery Initiatives - Quiver Quantitative
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Hallett David - Moomoo
Recursion (NASDAQ: RXRX) CSO RSU tax withholding on 26,657 shares - Stock Titan
Recursion (NASDAQ: RXRX) CEO has 62,701 shares withheld for RSU taxes - Stock Titan
Recursion Pharmaceuticals (RXRX) CFO reports tax-related share withholding - Stock Titan
22,821 RXRX shares withheld for taxes as Recursion director reports RSU event - Stock Titan
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - The Chronicle-Journal
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News - TechStock²
Recursion Pharmaceuticals stock hits 52-week low at $2.79 - Investing.com India
Recursion Pharmaceuticals stock hits 52-week low at $2.79 By Investing.com - Investing.com Canada
RXRX Stock Price and Chart — NASDAQ:RXRX - TradingView
Q4 Earnings Estimate for RXRX Issued By KeyCorp - MarketBeat
Nvidia’s expanding role in AI-driven drug discovery, clinical research could fuel growth, says Goldman Sachs - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5 - Moomoo
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating - marketscreener.com
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities - The Globe and Mail
Recursion Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.64, Implies 118% Upside - TradingView
Recursion Pharmaceuticals (RXRX) stock dips while market gains: Key facts - MSN
Recursion Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RXRX) 2026-05-13 - Seeking Alpha
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
Recursion Q1 2026 slides: AI pipeline advances amid revenue challenges - Investing.com
State Street (RXRX) discloses 28.49M-share, 5.5% stake in Recursion - Stock Titan
4 top AI stocks to hold for a decade | 2026-05-12 | Investing News - Stockhouse
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks - simplywall.st
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Recent Clinical And Cost Management Updates - Sahm
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M - MSN
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
A Look At Recursion Pharmaceuticals (RXRX) Valuation After Clinical Updates And FDA Discussions - Yahoo Finance
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 By Investing.com - Investing.com Australia
Recursion Pharmaceuticals director Christopher Gibson sells $134,800 - Investing.com
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Director |
May 07 '26 |
Sale |
3.37 |
40,000 |
134,800 |
926,556 |
| Borgeson Blake | Director |
May 05 '26 |
Sale |
3.52 |
30,000 |
105,600 |
6,199,863 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):